title: Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.
abstract: This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithromycin and rifabutin in volunteers with or without human immunodeficiency virus infection. Daily dosing with the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal symptoms and neutropenia. No significant pharmacokinetic interactions were found between these drugs.
authors: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. RHafner@niaid.nih.gov
authors: R
authors: R
authors: Hafner
authors: J
authors: J
authors: Bethel
authors: H C
authors: HC
authors: Standiford
authors: S
authors: S
authors: Follansbee
authors: D L
authors: DL
authors: Cohn
authors: R E
authors: RE
authors: Polk
authors: L
authors: L
authors: Mole
authors: R
authors: R
authors: Raasch
authors: P
authors: P
authors: Kumar
authors: D
authors: D
authors: Mushatt
authors: G
authors: G
authors: Drusano
mesh_terms: D000328:Adult; D019540:Area Under Curve; D017963:Azithromycin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D004338:Drug Combinations; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics* / Q000494:pharmacology; D005260:Female; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D008297:Male; D017828:Rifabutin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D004338:Drug Combinations; D017828:Rifabutin; D017963:Azithromycin